Apigenin was demonstrated to inhibit inflammation and inflammation-induced carcinogenesis by suppressing STAT3 and NF-κB signalling in vivo, and showed a protective effect against colitis-associated cancer by reducing the tumour volume in addition to decreasing neutrophil infiltration [97]. This evidence concerns the gene STAT3 and neoplasm.